Kornimate/medical-research-clean huggingface dataset:
a study of peg-somatropin in the treatment of children with idiopathic short stature

Conditions: Dwarfism

Summary: this study aims to explore the optimal dose of pegylated recombinant human growth hormone (peg-rhgh) injection to treat children with idiopathic short stature (iss), evaluate its safety and efficacy, and provide scientific and reliable evidence for the medication dosage in phase iii clinical study.


Eligibility criteria:
inclusion criteria: * boys are between 4 and 9 years of age and girls are between 4 and 8 years of age. * height \<-2 sd for chronological age. * growth velocity\<5.0 cm/yr. * gh peak concentration ≥10.0 ng/ml in two different stimulation tests. * the difference of bone age (ba) and chronological age (ca) is within -2 to +2. * igf-1 concentration is between -2 sds to +2 sds. * prepubertal status(tanner stage i). * birth weight within the normal range. * growth hormone treatment-naive. * subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign informed consent. exclusion criteria: * subjects with abnormal liver and kidney functions (alt \> upper limit of normal value; cr \> upper limit of normal value). * subjects are positive for anti-hbc, hbsag or hbeag in hepatitis b virus tests. * subjects with known highly allergic constitution or allergy to investigational product or its excipient. * subjects with systemic chronic disease and immune deficiency. * patients diagnosed with tumor. * patients with mental disease. * patients with other types of abnormal growth and development. 1. growth hormone deficiency (ghd) (confirmed by gh stimulation test); 2. turner syndrome (confirmed by karyotype test of girls); 3. noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with skin disease and congenital heart disease, missense mutation of the protein tyrosine phosphatase, non-receptor type 11 (ptpn11) gene on chromosome 12 for half of the patients, for both male and female patients); 4. laron sydrome (confirmed by igf-1 generation test); 5. small for gestational age ( the birth height or weight is below the tenth percentile or 2 sd, with catch-up growth uncompleted at 2 years old). * growth disorders caused by malnutrition or hypothyroidism (thyroid function test). * congenital skeletal abnormalities or scoliosis, claudication. * subjects with impaired glucose regulation (igr) (including impaired fasting glucose (ifg) and/or impaired glucose tolerance (igt) ) or diabetes). * subjects with abnormal electrolyte, blood gas analysis (vein), creatine kinase. * subjects who took part in other clinical trials within 3 months. * subjects who received medications which may interfere gh secretion or gh function, or other hormones within 3 months (such as sex steroids, glucocorticoids, etc.). * for patients with potential high tumor risks such as tumor markers exceed normal range and some other relative information, they may be excluded from the treatment. * other conditions which is inappropriate for this study in the opinion of the investigator.
adding prednisolone during ovulation induction with cc in lean women with cc resistant pcos

Conditions: Infertility; Polycystic Ovarian Syndrome

Summary: the purpose of this study is to evaluate the effect of concomitant administration of prednisolone during use of clomiphene citrate (cc) for induction of ovulation in infertile lean women having cc resistant polycystic ovarian syndrome (pcos).

women will be randomly divided into two groups; cc-prednisolone group and cc-placebo group. women in the cc-prednisolone group will receive cc (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone tablet (5 mg/day for 10 consecutive days from day 2 of the cycle). women in the cc-placebo group will receive cc alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid tablet (0.5 mg/day for 10 consecutive days from day 2 of the cycle). transvaginal sonography (tvs) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. when there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 iu of human chorionic gonadotropin (hcg) and timed intercourse will be advised. if there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. ovulation will be documented by tvs scan one week after triggering of oocyte maturation and will be confirmed by assessing the mid-luteal serum progesterone level. each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle

Eligibility criteria:
inclusion criteria: * infertile lean women with pcos as defined by the rotterdam criteria. * cc resistance (defined as failure of ovulation after receiving 150 mg/day of cc for 5 consecutive days per cycle, for at least 3 consecutive cycles). exclusion criteria: * age \ 35 years. * body mass index (bmi) \ 25 kg/m2. * presence of any infertility factor other than anovulatory pcos. * previous history of ovarian surgery or surgical removal of one ovary. * previous exposure to cytotoxic drugs or pelvic irradiation. * oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. * metabolic or hormonal abnormalities

Keywords: pcos clomiphene citrate resistant prednisolone
magnetic resonance imaging (mri) of appendicitis in children

Conditions: Appendicitis

Summary: study to find out if mri can diagnose appendicitis in children as well as or better than ct scan and/or ultrasound scan performed at the same time. no additional contrast material or sedation will be used to perform the mri.


Eligibility criteria:
inclusion criteria: * age 8-18 years, referred from emergency department for suspected appendicitis and receiving either ct scan or ultrasound of the abdomen for diagnosis exclusion criteria: * failure to pass mri metal screening. claustrophobia or need for sedation due to inability to hold still.

Keywords: appendicitis children magnetic resonance imaging
muscle architecture and muscle strength in fibromyalgia

Conditions: Fibromyalgia; Sarcopenia; Muscle Weakness

Summary: the goal of this observational study is to determine whether there is decrease in muscle mass and muscle strength in fibromyalgia syndrome (fms) patients in comparison to controls. and to determine whether these parameters are correlated with clinical ones. briefly the main questions investigators aims to answer are: * is there a significant difference in muscle morphology between fms and controls? * is there a significant difference in muscle strength between fms and controls? * is there a relationship between muscle thickness and pennation angle of the quadriceps, gastrocnemius medialis, gastrocnemius lateralis and tibialis anterior muscles and disease activity, pain and functionality? * is there a correlation between muscle strength in fms and disease activity, pain and functionality?

fibromyalgia syndrome (fms) was named by smythe and moldofsky when they defined tender points in 1970s. it is defined as chronic, generalized musculoskeletal pain accompanying with fatigue, sleep disturbance , cognitive and somatic disturbance. fms has variable prevalence as %0,7-11 and usually affects middle aged women. it is second most common rheumatologic disease after osteoarthritis and thought to be the most common reason for musculoskeletal pain in middle aged women. recent studies have reported that both sarcopenia and decreased muscle strength occur in patients with chronic inflammatory diseases such as rheumatoid arthritis. there are concerns that sarcopenia may affect exercise tolerance, activities of daily living, and ultimately have a negative impact on cardiovascular fitness and physical and emotional well-being. on the other hand there is researches that support inflammation-driven pathways in the pathogenesis of fibromyalgia. given the risk of pain related reduction in physical activity, patients are expected to have accelerated muscle wasting , decreased muscle strength and endurance and functionality. however, there is no study that focused on muscle architecture and strength in fms. this led us to design our study which will evaluate patients lower extremity muscles' thickness and pennation angles by ultrasound , most daily used muscles' strength by dynamometer, functionality by timed-up test and try to find whether there is a correlation between these parameters and patients' disease activity which will be determined with fms specific scales.

Eligibility criteria:
inclusion criteria: * meeting the 2016 acr (american college of rheumatology) diagnostic criteria. * diagnosed at least 1 year ago. exclusion criteria: * patients diagnosed with other rheumatological diseases, muscle diseases, or neuropathies. * patients with a history of trauma affecting muscle morphology. * patients engaging in regular exercise (at least 3-4 times a week for a minimum of 40 minutes). * patients with uncontrolled comorbid diseases

Keywords: muscle strength musculoskeletal ultrasound
can therapy alter cns processing of chronic pain: a longitudinal study

Conditions: Chronic Pain

Summary: the purpose of this study is to investigate whether a psycho-therapeutic approach, group cognitive behavioral therapy (cbt) plus a relapse prevention program, therapeutic interactive voice response (tivr), modifies the dysfunctional sensory, emotional, and cognitive neural circuitry associated with chronic pain.


Eligibility criteria:
inclusion criteria: * at least 12 months of muscular-skeletal, non-neuropathic pain exclusion criteria: * malignancy causing or influencing chronic pain * radiation or chemotherapy, or metastatic cancer of any type * reflex sympathetic dystrophy (rsd) and/or neuropathic pain * neurological disorders such as epilepsy or stroke, or other medical conditions * psychiatric disorders * opioid medication use for pain management * past year history of illicit drug use that can result in altered cognition * pregnancy * exceeding weight limit of the mri scanner * incompatible implants due to mri safety * awaiting pain related surgical procedure * involved in pain-related litigation

Keywords: acute pain low back pain back pain functional magnetic resonance imaging (fmri) cognitive behavioral therapy pain education
the effect of momordica charantia supplementation on blood glucose levels

Conditions: Glucose Intolerance

Summary: the study is a randomized, cross-over, double blind, controlled trial in which study participants will receive two 4-week interventions with a washout period of 4 weeks between interventions. study subjects will visit the research facility before and after each intervention period for a test day. in the third intervention week participants are provided with a 3-day controlled diet and glucose responses will be monitored via a continuous glucose monitoring device.

bitter gourd (bg) (momordica charantia), is a highly nutritive vegetable from the cucumber family. the objective is to assess the impact of 4-week bg supplementation on blood glucose levels and glucose tolerance in subjects with an impaired fasting glucose or with an impaired glucose tolerance and to evaluate how bg supplements modulate glucose response curves during meal intake. the study is a randomized, cross-over, double blind, controlled trial in which study participants will receive two 4-week interventions with a washout period of 4 weeks between interventions. study subjects will visit the research facility before and after each intervention period for a test day. in the third intervention week participants are provided with a 3-day controlled diet and glucose responses will be monitored via a continuous glucose monitoring device. the intervention will be a 4-week intervention with 2.4g/d dried bitter-gourd supplements and a reference intervention with 2.4g/d dried cucumber supplements. the main study parameter is fasting levels of plasma glucose and 2hour plasma glucose after a 75-gram ogtt.

Eligibility criteria:
inclusion criteria: * age 50-75yrs * bmi \>25 kg/m2 * having veins suitable for blood sampling via a catheter * having one or more of the following criteria: * hba1c \> 5.7% * fasting glucose \>5.6mmol/l * two-hour glucose levels \>7.8 mmol/l on the 75-g oral glucose tolerance test . exclusion criteria: * history of gastro-intestinal surgery or having (serious) gastro-intestinal complaints * history of liver dysfunction (cirrhosis, hepatitis) or liver surgery * kidney dysfunction (self-reported) * use of medication/supplements that may influence the study results, such as medicines known to interfere with glucose homeostasis. * anaemia (hb values \<7.5 for women and \<8.5 for men) * reported slimming, medically prescribed or other extreme diets * reported weight loss or weight gain of \> 5 kg in the month prior to pre-study screening * not willing to give up blood donation during the study * current smokers * alcohol intake ≥4 glasses of alcoholic beverages per day * abuse of illicit drugs * food allergies for products that we use in the study * participation in another clinical trial at the same time * being an employee of the food, health \& consumer research group of wageningen food \& biobased research or dept. human nutrition and health of wageningen university.

Keywords: bitter gourd pre-diabetics glucose response
identification of graphic markers of neurocognitive disorders (mg)

Conditions: Alzheimer Disease; Primary Progressive Aphasia; Neurocognitive Disorders

Summary: the diagnosis of neurocognitive disorders such as early alzheimer's disease (ad) or primary progressive aphasia (ppa) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. however, several studies have shown that graphic parameters are affected in people with moderate to severe alzheimer's disease. the use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. the use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries. the overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with ppa, early-stage alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.


Eligibility criteria:
inclusion criteria: * = \> 50 years old for control group : * not have a diagnosis of minor or major neurocognitive disorder. for ad : * have mild stage alzheimer's disease: 1/ be diagnosed according to icd-10 criteria for the following conditions: alzheimer's disease and 2/ have an mmse score between 20 and 27, corresponding to a major tnc of mild stage or have a diagnosis of minor tnc with an mmse score between 25 and 30, the validity period of a previously done mmse is 3 months. for ppa : * have primary progressive aphasia according to the gorno-tempini criteria (gorno-tempini et al., 2011) and have an mmse score between 20 and 27, corresponding to major mild tnc or have a diagnosis of minor tnc with an mmse score between 25 and 30, the validity period of a previously made mmse is 3 months. exclusion criteria: * presence of pathologies of the dominant upper limb(s) (left, right or ambidextrous lateralization) disabling such as osteoarthritis, finger amputation, etc. * history of stroke. * illiterate person. * participate in a concurrent experimental clinical study, to avoid interference with our study. * not understand oral and written french. the speakers are french-speaking and the language task is performed in french.

Keywords: graphic markers
antibiotic therapy of acute uncomplicated colonic diverticulitis

Conditions: Colonic Diverticulitis

Summary: the purpose of this study is to evaluate if antibiotic therapy is necessary for treatment of uncomplicated colonic diverticulitis. the hypothesis is that patients with acute uncomplicated colonic diverticulitis will recover the condition without antibiotic therapy and the lack of antibiotic therapy will not lead to complications. the patients will be randomized to conservative treatment with and without antibiotic therapy.


Eligibility criteria:
inclusion criteria: * adults with ct sign of acute colonic uncomplicated diverticulitis * elevated crp and lpk * temp.38c or more exclusion criteria: * patients with peritonitis, sepsis or ct- sign of complicated diverticulitis with abscesses or free abdominal air * pregnancy * immunological incompetence and immunosuppressive therapy

Keywords: colonic diverticulitis diverticular disease antibiotic therapy
a clinical investigation of recovery following hip resurfacing or total hip arthroplasty

Conditions: Osteoarthritis; Rheumatoid Arthritis; Arthritis; Traumatic Arthritis

Summary: the primary purpose of this study is to compare early functional outcomes in patients undergoing hip resurfacing and total hip arthroplasty with the m2a-magnum™ using more objective measures of function.


Eligibility criteria:
inclusion criteria: * patients requiring hip arthroplasty exclusion criteria: * patients with sensory, neurological, or general health conditions that alter perception of their limb in space * patients with vestibular disorders
open -label,cross over trail evaluating the glycemic impact of peach varieties in healthy adullts

Conditions: Blood Glucoe

Summary: this study aims to evaluate the effect of different peach varieties on the glycemic index (gi) in healthy adult participants. while peaches are generally classified as low-gi fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. by assessing and comparing the gi values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

this study aims to evaluate the effect of different peach varieties on the glycemic index (gi) in healthy adult participants. while peaches are generally classified as low-gi fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. by assessing and comparing the gi values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

Eligibility criteria:
inclusion criteria:• healthy male and female adults aged 18-50 years * bmi between 18.5-24.9 kg/m² * normal fasting blood glucose (\<100 mg/dl) * willingness to adhere to the study protocol exclusion criteria:• diagnosed diabetes, metabolic syndrome, or any glucose metabolism disorder * use of medications or supplements that affect glucose levels * allergy to peaches or intolerance to test/reference foods * pregnant or breastfeeding women * smoking or use of recreational drugs

Keywords: glycemic index glycemic load
3d airway model for pediatric patients

Conditions: Congenital Heart Disease

Summary: to determine the correct size of endotracheal tubes (ett) for endotracheal intubation of pediatric patients is no menial task. although new methods have been investigated to determine ett size, and the three-dimensional (3d) printing technology has been successful in the field of surgery, there are not many studies in the field of anesthesia. the purpose of this study is to evaluate the accuracy of a 3d airway model for prediction of the correct ett size, and compare the results with a conventional age-based formula in pediatric patients.

to determine the correct size of endotracheal tubes (ett) for endotracheal intubation of pediatric patients is no menial task. although new methods have been investigated to determine ett size, and the three-dimensional (3d) printing technology has been successful in the field of surgery, there are not many studies in the field of anesthesia. the purpose of this study is to evaluate the accuracy of a 3d airway model for prediction of the correct ett size, and compare the results with a conventional age-based formula in pediatric patients. : thirty five pediatric patients under 6 years of age who were scheduled for congenital heart surgery. in the pre-anaesthetic period, the patient's computed tomography (ct) images were converted to stl files using the 3d conversion program. an fdm type 3d printer was used to print 3d airway models from the sub-glottis to the upper carina. ett size was selected by inserting various sized cuffed-etts to a printed 3d airway model.

Eligibility criteria:
inclusion criteria: * children under 6 years of age (range 4 days to 61 months) scheduled for surgery for congenital heart disease with chest computed tomography (ct) images including upper airways exclusion criteria: * pediatric patients with intubation or tracheostomy before general anesthesia due to underlying disease * small sized airway with inner diameter \<3.0 mm because of pre-term or low birth weight * unstable vital signs during induction * history of difficult intubation * emergency surgery where printing a 3d airway model in advance was not possible